Harmony Biosciences Holdings ( (HRMY) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Harmony Biosciences shares came under pressure after Deutsche Bank flagged higher patent risks around its key sleep disorder drug, Wakix, following a Delaware bench trial in which the judge appeared to lean against the company. The bank warned that Wakix could face a credible challenge to its market exclusivity as soon as 2026.
In response to these concerns, Deutsche Bank downgraded Harmony Biosciences to Hold and reduced its price target on the stock. The shift in rating reflects growing uncertainty over the company’s long‑term revenue prospects if Wakix loses its competitive edge earlier than investors had expected.
More about Harmony Biosciences Holdings
YTD Price Performance: -8.10%
Average Trading Volume: 675,030
Technical Sentiment Signal: Sell
Current Market Cap: $2.03B
For further insights into HRMY stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.